Wintrust Investments LLC Has $85,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Wintrust Investments LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 35.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 522 shares of the company’s stock after selling 285 shares during the quarter. Wintrust Investments LLC’s holdings in Zoetis were worth $85,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Finally, Asset Planning Inc acquired a new position in shares of Zoetis in the 4th quarter worth approximately $58,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on ZTS shares. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Piper Sandler upped their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Barclays upped their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Morgan Stanley reduced their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by company insiders.

Zoetis Stock Performance

ZTS stock opened at $160.03 on Friday. The business’s fifty day moving average is $166.86 and its 200-day moving average is $176.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $71.66 billion, a P/E ratio of 29.26, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.